Breaking Down SG&A Expenses: Merck & Co., Inc. vs Verona Pharma plc

A Tale of Two Companies: SG&A Expenses Over Time

In the world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Merck & Co., Inc. and Verona Pharma plc have shown contrasting trends in their SG&A expenses. From 2014 to 2023, Merck's expenses have fluctuated, peaking in 2014 and 2019, with a slight decline in 2020. Despite these fluctuations, Merck's SG&A expenses have remained relatively stable, averaging around $10 billion annually.

In contrast, Verona Pharma's SG&A expenses have seen a dramatic increase, growing by over 2,600% from 2014 to 2023. This surge reflects Verona's aggressive expansion and investment in administrative capabilities. While Merck's expenses dwarf those of Verona, the latter's rapid growth highlights its potential in the competitive pharmaceutical landscape. Understanding these trends offers valuable insights into each company's strategic priorities and market positioning.